Lepu Medical Technology Co (300003) Q2 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was ¥3.37 billion, down 0.43% year-over-year; net profit attributable to shareholders was ¥690.93 million, down 0.91% year-over-year; adjusted net profit (excluding non-recurring items) rose 2.33% year-over-year.

• Operating cash flow increased significantly by 300.52% year-over-year to ¥636.36 million.

• The company maintained its leadership in cardiovascular medical devices, expanded its innovative product pipeline, and achieved notable progress in international markets.

• A cash dividend of ¥1.6275 per 10 shares (pre-tax) was proposed, totaling ¥300 million.

Financial highlights

• Gross margin for the period was 64.26%.

• Basic and diluted EPS were both ¥0.3748.

• Total assets at period-end were ¥25.36 billion, up 3.20% from the previous year-end; net assets attributable to shareholders were ¥15.80 billion, up 3.92%.

• R&D investment reached ¥532.83 million, up 2.86% year-over-year.

• Overseas sales grew 6.91% year-over-year, with gross margin up 3.19 percentage points.

Outlook and guidance

• The company will continue to focus on innovation, internationalization, and consumer healthcare, with a robust pipeline in cardiovascular, structural heart, and AI-driven medical products.

• Ongoing expansion in international markets and digital health is expected to drive future growth.